Insider Transactions Report for Acrivon Therapeutics, Inc.

Peter Blume-Jensen, President and CEO of Acrivon Therapeutics, Inc., disposed of 13,729 shares of Common Stock on May 21, 2026, at a price of $1.79 per share. This transaction was a result of shares withheld to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units. Following this transaction, Mr. Blume-Jensen directly owns 2,245,317 shares. Additionally, Kristina Masson, EVP - Business Operations, holds 386,343 shares indirectly, with both officers having spousal relationship and disclaiming beneficial ownership except to the extent of their pecuniary interest.